[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
OBJECTIVE
We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for 154 symptomatic benign prostatic hyperplasia (BPH) patients who also suffered from overactive bladder (OAB) symptoms.


METHODS
Naftopidil and tamsulosin hydrochloride were administered for eight weeks. The international prostate symptom score (IPSS), QOL index, maximum flow rate (Q(max)), residual urine volume (RUV) and side effect profile were determined before the administration and after eight weeks of treatment.


RESULTS
In the naftopidil group, seven parameters of IPSS and QOL index were improved significantly at the endpoint compared to the baseline. In the tamsulosin group, all parameters except frequency and straining were also improved. Both drugs improved the Q(max) at the endpoint, too. The RUV did not change in both groups. Naftopidil was also superior to tamsulosin hydrochloride regarding general treatment outcome by the Japanese clinical guideline of urinary disturbance.


CONCLUSIONS
This study demonstrated that naftopidil was clinically efficacious in the treatment of BPH patients with OAB.
Department of Urology, Jikei University School of Medicine.
Shigeru
S
Kosugi
Isao
I
Ikemoto
Akira
A
Furuta
Tatsuya
T
Shimomura
Hiroshi
H
Kiyota
Yasuyuki
Y
Suzuki
Kouichi
K
Kishimoto
Shin
S
Egaway
Shinichiro
S
Torii
Hitoshi
H
Shirai
Hiroyuki
H
Takeuchi
Kazuhiro
K
Abe
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications*
D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; D013449:Sulfonamides; D000077409:Tamsulosin; C064357:naftopidil